A Phase III Long Term Study of K-877 Extended Release Tablet
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of K-877 Extended Release (ER) once daily for 52 weeks
in the morning or evening in dyslipidema.The starting dose of the ER tablet will be 0.2
mg/day. If the efficacy is insufficient, it will investigate the safety and efficacy of 0.4
mg/day.